Cargando…
Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment
Ovarian cancer (OC) is a lethal gynecological malignancy with a five-year survival rate of only 46%. Development of resistance to platinum-based chemotherapy is a common cause of high mortality rates among OC patients. Tumor and transcriptomic heterogeneity are drivers of platinum resistance in OC....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348737/ https://www.ncbi.nlm.nih.gov/pubmed/35921335 http://dx.doi.org/10.1371/journal.pone.0271584 |
_version_ | 1784761980407513088 |
---|---|
author | Sriramkumar, Shruthi Metcalfe, Tara X. Lai, Tim Zong, Xingyue Fang, Fang O’Hagan, Heather M. Nephew, Kenneth P. |
author_facet | Sriramkumar, Shruthi Metcalfe, Tara X. Lai, Tim Zong, Xingyue Fang, Fang O’Hagan, Heather M. Nephew, Kenneth P. |
author_sort | Sriramkumar, Shruthi |
collection | PubMed |
description | Ovarian cancer (OC) is a lethal gynecological malignancy with a five-year survival rate of only 46%. Development of resistance to platinum-based chemotherapy is a common cause of high mortality rates among OC patients. Tumor and transcriptomic heterogeneity are drivers of platinum resistance in OC. Platinum-based chemotherapy enriches for ovarian cancer stem cells (OCSCs) that are chemoresistant and contribute to disease recurrence and relapse. Studies examining the effect of different treatments on subpopulations of HGSOC cell lines are limited. Having previously demonstrated that combined treatment with an enhancer of zeste homolog 2 inhibitor (EZH2i) and a RAC1 GTPase inhibitor (RAC1i) inhibited survival of OCSCs, we investigated EZH2i and RAC1i combination effects on HGSOC heterogeneity using single cell RNA sequencing. We demonstrated that RAC1i reduced expression of stemness and early secretory marker genes, increased expression of an intermediate secretory marker gene and induced inflammatory gene expression. Importantly, RAC1i alone and in combination with EZH2i significantly reduced oxidative phosphorylation and upregulated Sirtuin signaling pathways. Altogether, we demonstrated that combining a RAC1i with an EZH2i promoted differentiation of subpopulations of HGSOC cells, supporting the future development of epigenetic drug combinations as therapeutic approaches in OC. |
format | Online Article Text |
id | pubmed-9348737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-93487372022-08-04 Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment Sriramkumar, Shruthi Metcalfe, Tara X. Lai, Tim Zong, Xingyue Fang, Fang O’Hagan, Heather M. Nephew, Kenneth P. PLoS One Research Article Ovarian cancer (OC) is a lethal gynecological malignancy with a five-year survival rate of only 46%. Development of resistance to platinum-based chemotherapy is a common cause of high mortality rates among OC patients. Tumor and transcriptomic heterogeneity are drivers of platinum resistance in OC. Platinum-based chemotherapy enriches for ovarian cancer stem cells (OCSCs) that are chemoresistant and contribute to disease recurrence and relapse. Studies examining the effect of different treatments on subpopulations of HGSOC cell lines are limited. Having previously demonstrated that combined treatment with an enhancer of zeste homolog 2 inhibitor (EZH2i) and a RAC1 GTPase inhibitor (RAC1i) inhibited survival of OCSCs, we investigated EZH2i and RAC1i combination effects on HGSOC heterogeneity using single cell RNA sequencing. We demonstrated that RAC1i reduced expression of stemness and early secretory marker genes, increased expression of an intermediate secretory marker gene and induced inflammatory gene expression. Importantly, RAC1i alone and in combination with EZH2i significantly reduced oxidative phosphorylation and upregulated Sirtuin signaling pathways. Altogether, we demonstrated that combining a RAC1i with an EZH2i promoted differentiation of subpopulations of HGSOC cells, supporting the future development of epigenetic drug combinations as therapeutic approaches in OC. Public Library of Science 2022-08-03 /pmc/articles/PMC9348737/ /pubmed/35921335 http://dx.doi.org/10.1371/journal.pone.0271584 Text en © 2022 Sriramkumar et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sriramkumar, Shruthi Metcalfe, Tara X. Lai, Tim Zong, Xingyue Fang, Fang O’Hagan, Heather M. Nephew, Kenneth P. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title | Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title_full | Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title_fullStr | Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title_full_unstemmed | Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title_short | Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
title_sort | single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348737/ https://www.ncbi.nlm.nih.gov/pubmed/35921335 http://dx.doi.org/10.1371/journal.pone.0271584 |
work_keys_str_mv | AT sriramkumarshruthi singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT metcalfetarax singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT laitim singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT zongxingyue singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT fangfang singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT ohaganheatherm singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment AT nephewkennethp singlecellanalysisofahighgradeserousovariancancercelllinerevealstranscriptomicchangesandcellsubpopulationssensitivetoepigeneticcombinationtreatment |